Literature DB >> 1606754

Postnatal development of T lymphocytes in a novel X-linked immunodeficiency disease.

F C Schmalstieg1, D P Wirt, L T Adkins, E G Brooks, S D Stansberry, L E Swischuk, A S Goldman.   

Abstract

We previously reported an X-linked combined immunodeficiency disease (CID) characterized by immune deficiencies and complicating infections that were more moderate than those found in severe CID (SCID). Since other unstudied males in the family died in infancy, we questioned whether this T cell defect was more profound in early life. Subsequently, the development of blood T cells in an affected newborn male was examined. T cells were virtually undetectable at 48 hr. Over the next several months, CD4+ T cells (principally CD45RO+) rose to levels similar to those found in older affected males, but CD8+ T cells developed more slowly and never attained levels found in other affected males. Thus, this disease in early life mimics SCID and may pose a higher risk of fatal infections to affected individuals during that period. Finally, we speculate that the genetic defect may disrupt intrathymic development or selection of T cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606754     DOI: 10.1016/0090-1229(92)90061-r

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  3 in total

Review 1.  Severe combined immune deficiencies due to defects of the common gamma chain-JAK3 signaling pathway.

Authors:  F Candotti; J J O'Shea; A Villa
Journal:  Springer Semin Immunopathol       Date:  1998

Review 2.  Thymopoiesis and T cell development in common gamma chain-deficient dogs.

Authors:  Peter J Felsburg; Brian J Hartnett; Terry A Gouthro; Paula S Henthorn
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

3.  Missense mutation in exon 7 of the common gamma chain gene causes a moderate form of X-linked combined immunodeficiency.

Authors:  F C Schmalstieg; W J Leonard; M Noguchi; M Berg; H E Rudloff; R M Denney; S K Dave; E G Brooks; A S Goldman
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.